Latest German Market News

Collins Foods unveiled ambitious growth plans at its 2025 Investor Day, spotlighting rapid expansion in Germany and operational enhancements in Australia and Europe. The company reaffirmed its FY26 profit growth targets, underpinned by digital innovation and brand modernization.

Bioxyne Limited has secured import permits and purchase orders worth A$5.1 million for medical cannabis in Germany, signaling strong early traction in a key European market.

Camplify Holdings reported a strategic refocus in FY25, delivering a strong operational turnaround in the second half and positioning itself for profitability in FY26. Despite a decline in gross transaction value, the company improved cost efficiency and expanded its membership and insurance offerings.

Sonic Healthcare delivered solid FY2025 results with 8% revenue growth and a 7% rise in net profit, setting the stage for an anticipated 19% earnings per share increase in FY2026.

Hansen Technologies reported robust FY25 results, driven by strong revenue growth, strategic contract wins, and deepening AI integration. The company’s expansion in Germany and sustainability leadership further underpin its positive outlook.

Arafura Rare Earths pushes forward with equity funding for its Nolans Project, targeting a €100 million investment from Germany’s Raw Materials Fund amid rising geopolitical tensions reshaping the rare earths landscape.

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.

Bioxyne Limited reports a record-breaking Q4 FY25 with revenue soaring 204% year-on-year and a strategic entry into the German market through a €3.2 million manufacturing agreement.

Little Green Pharma reported a robust June 2025 quarter with record cash receipts and expanding European footprint, highlighted by a new production capacity in Denmark and the launch of its CherryCo brand in Germany.

Collins Foods delivered resilient FY25 results with solid revenue growth and a strategic pivot towards German market expansion, while addressing profitability challenges in the Netherlands.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.